GlassScriptPhysician profile
Samer Alamir
NPI 1649322843
$7,158.98
in general payments reported to CMS, 2019-2025
21 companies · $3,712 in 2025
The $3,712 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $244 · 2020: $21.17 · 2021: $192 · 2022: $95.36 · 2023: $927 · 2024: $1,969 · 2025: $3,712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,605 · Education: $2.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,604.94 |
| Education | $2.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,757.76 | 2021-2025 | Vraylar |
| Vanda Pharmaceuticals INC. | $862.66 | 2024-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $495.74 | 2023-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $438.33 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $400.26 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $389.80 | 2022-2025 | Caplyta |
| Indivior INC. | $374.67 | 2019-2025 | Sublocade |
| E.R. Squibb & Sons, L.L.C. | $355.48 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $332.27 | 2023-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $330.21 | 2024-2025 | Qelbree |
| Axsome Therapeutics, INC. | $276.31 | 2024-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $244.35 | 2023-2025 | Trintellix, Vyvanse |
| Janssen Pharmaceuticals, INC | $199.29 | 2022-2025 | Spravato |
| Noven Therapeutics, LLC | $193.16 | 2023-2025 | Xelstrym, Secuado |
| Braeburn INC. | $154.36 | 2023-2025 | Brixadi |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $105.25 | 2024-2025 | Zurzuvae |
| Almatica Pharma LLC | $94.23 | 2023-2024 | Loreev Xr |
| Tms Neurohealth Centers INC. | $78.67 | 2025 | Tms Neurohealth Centers INC. |
| Corium, LLC | $55.01 | 2023-2024 | Azstarys |
| Allergan, INC. | $17.25 | 2020 | |
| Validus Pharmaceuticals LLC | $3.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samer Alamir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.